← the graveyard
Gemcitabine Hydrochloride Injection
no longer on the FDA list · Oncology · Removed 2026-09-12
This drug was removed from the FDA's shortage list on 2026-09-12. The FDA does not say why a listing is removed. What follows is the last record we saw, from the 2026-09-11 snapshot, when its status was being discontinued. It is an archive, not current information, and it is not counted in any figure elsewhere on this site.
- Manufacturers listed (last seen)
- Hospira, Inc., a Pfizer Company
- Machine-readable
- JSON for this drug
Presentations as last listed (3)
| Presentation | Company | Availability | Updated |
|---|---|---|---|
| Gemcitabine Hydrochloride, Injection, 1 g/26.3 mL (38 mg/mL), sterile solution in a single-dose glass vial NovaPlus (NDC 0409-0181-25) | Hospira, Inc., a Pfizer Company | unknown | 09/11/2025 |
| Gemcitabine Hydrochloride, Injection, 200 mg/5.26 mL (38 mg/mL), sterile solution in a single-dose glass vial NovaPlus (NDC 0409-0183-25) | Hospira, Inc., a Pfizer Company | unknown | 09/11/2025 |
| Gemcitabine Hydrochloride, Injection, 2 g/52.6 mL (38 mg/mL), sterile solution in a single-dose glass vial NovaPlus (NDC 0409-0182-25) | Hospira, Inc., a Pfizer Company | unknown | 09/11/2025 |
History
Daily tracking of this drug began 2026-08-25 (the first day of the archive).
- 2026-09-12 — Gemcitabine Hydrochloride Injection was removed from the FDA list (was being discontinued)
Each daily snapshot is compared with the one before it; status changes, availability-wording revisions, and arrivals or removals are listed here. A change the FDA makes and reverses between two snapshots is not seen. Every daily record is kept in the public repository.
Not medical advice. ShortSupply republishes the FDA's drug-shortage data with history added. Talk to your pharmacist or prescriber about your situation — never change medication based on this site.